Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc